Besifloxacin

DRUG6 trials

Sponsors

Bausch & Lomb Incorporated, Frank A. Bucci, Jr., M.D., McGill University Health Centre/Research Institute of the McGill University Health Centre

Conditions

Acute Bacterial ConjunctivitisBacterial ConjunctivitisBacterial KeratitisCataractsHealthy

Phase 1

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

CompletedNCT00905762

Bausch & Lomb IncorporatedHealthy

Start: 2009-03-31End: 2009-04-30Updated: 2011-12-09

Phase 2

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

CompletedNCT00972777

Bausch & Lomb IncorporatedBacterial Conjunctivitis

Start: 2009-10-31End: 2011-02-28Updated: 2012-03-29

Phase 3

A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

CompletedNCT00348348

Bausch & Lomb IncorporatedAcute Bacterial Conjunctivitis

Start: 2006-06-30End: 2007-07-31Updated: 2015-03-24

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

TerminatedNCT01740388

Bausch & Lomb IncorporatedBacterial Conjunctivitis

Start: 2013-02-28End: 2013-11-30Updated: 2014-10-01

Phase 4

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

CompletedNCT01296191

Frank A. Bucci, Jr., M.D.Cataracts

Start: 2011-05-31End: 2013-01-31Updated: 2020-12-22

Unknown Phase

Besifloxacin in Bacterial Keratitis

CompletedNCT02497365

McGill University Health Centre/Research Institute of the McGill University Health CentreBacterial Keratitis

Start: 2015-09-30End: 2019-07-31Updated: 2023-10-19

Related Papers

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%

PLoS ONE2020-08-259 citations

Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.

2012-05-0121 citations

Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.

2011-01-0134 citations